Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Active Biotech News

    0,0357 € +0,28% +0,0001 €
    08:08:11 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0BLFX
    ISIN: SE0001137985
    US-Symbol: ATVBF
    Typ: Aktie

    Active Biotech News

    01.06.22 - GlobeNewswire
    Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage
    Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa ...
    19.05.22 - GlobeNewswire
    Annual General Meeting of Active Biotech AB
    The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, ...
    18.05.22 - GlobeNewswire
    FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
    Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug ...
    28.04.22 - GlobeNewswire
    Annual Report 2021 Active Biotech AB (publ)
    Active Biotech's Annual Report 2021 is now available for download at  www.activebiotech.com . The Annual Report will only be digitally distributed.
    26.04.22 - GlobeNewswire
    Active Biotech strengthens the patent protection for laquinimod in eye disorders
    Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent ...
    21.04.22 - GlobeNewswire
    Active Biotech Interim Report Q1 2022
    FIRST QUARTER IN BRIEF
    20.04.22 - GlobeNewswire
    Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
    The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the ...
    31.03.22 - GlobeNewswire
    Number of shares and votes in Active Biotech
    The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees ...
    25.03.22 - GlobeNewswire
    Correction: Active Biotech Year End Report 2021
    The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the ...
    09.02.22 - GlobeNewswire
    Active Biotech: Year End Report 2021
    FOURTH QUARTER IN BRIEF
    09.02.22 - GlobeNewswire
    Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis
    Lund, February 9, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, ...
    07.02.22 - GlobeNewswire
    Active Biotech announces first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma
    Lund Sweden, February 7, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the combination part of the phase Ib/IIa ...
    04.01.22 - GlobeNewswire
    Active Biotech Appoints Erik Vahtola as Chief Medical Officer
    Lund, January 4, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer (CMO), effective ...
    15.12.21 - GlobeNewswire
    Preclinical tasquinimod data presented at ASH 2021 available on Active Biotech’s website
    Lund, December 15, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule ...
    10.12.21 - GlobeNewswire
    Active Biotech's nomination committee appointed
    In accordance with a decision made by the Annual General Meeting held on May 19, 2021, the Nomination Committee shall comprise the representatives for the three largest ...
    10.12.21 - GlobeNewswire
    First subject dosed in phase I clinical study with eye-drop formulation of laquinimod  
    Lund, December 10, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in the phase I clinical study of the newly developed ...
    30.11.21 - GlobeNewswire
    Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech’s partner NeoTX at SITC 2021
    Lund, Sweden — November 30, 2021 – Active Biotech and its partner NeoTX announced that the preclinical data on naptumomab enhancing the potency of CAR-T cells was presented ...
    09.11.21 - GlobeNewswire
    Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Lund, November 9, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today a presentation on naptumomab estafenatox (naptumomab, NAP), at ...
    04.11.21 - GlobeNewswire
    New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
    Lund, November 4, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule ...
    04.11.21 - GlobeNewswire
    Active Biotech Interim report January - September 2021  
    “We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung ...

    Newssuche

    Videos

    newspaper
    08:40 Uhr +22,09%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »